Efficacy of fludarabine & cyclophosphamide therapy for patients with relapsed and refractory low-grade lymphoproliferative disorders

Abstract

Fludarabine (FAMP) is reported to give a single-agent response rate of -50% in previously treated patients (pts) with CLL or low-grade NHL. Laboratory studies have shown that the cellular repair of cyclophosphamide (CYCLO)-induced DNA damage is inhibited by FAMP. Based on these observations, since 10/96 we have treated pts with relapsed or refractory chronic lymphoproliferative disorders with FAMP & CYCLO in combination. To July 2000, 35 pts have been treated and 34 have data available (11 with follicular NHL, 14 CLL, 2 PLL, 1 mantle-cell, 6 Waldenstrom's). The median number of prior therapies was 3 (range 0-6) ; 4 were previously untreated, 21 relapsed, and 9 refractory. Prior chemotherapy ..